SPOTLIGHT: Chemo combo increases survival

A new study indicates that a combination of chemotherapy drugs can increase the five-year survival rates of women with metastatic, node-positive breast cancer by 7 percent. But researchers warn of serious side effects. Story

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.